AML-Erhaltungstherapie: Cytarabin intensivieren oder Anthrazyklin dazu?
Crossref DOI link: https://doi.org/10.1007/s15015-016-2303-x
Published Online: 2016-02-15
Published Print: 2016-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Neumaier, Judith
Text and Data Mining valid from 2016-02-01